Alexion Pharmaceuticals Inc. Release: Researchers To Present New Data On Asfotase Alfa In Pediatric Patients With Hypophosphatasia At The American Society For Bone And Mineral Research 2014 Annual Meeting

CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that new data from multiple studies of asfotase alfa in pediatric patients with hypophosphatasia (HPP) will be presented at the American Society for Bone and Mineral Research (ASBMR) 2014 Annual Meeting, which takes place September 12-15, 2014 in Houston, Texas. The meeting will feature a late-breaking abstract of survival data in pediatric patients with HPP at high risk of death who were treated with asfotase alfa, along with results from two studies in patients with perinatal, infantile and juvenile HPP who were treated with asfotase alfa for up to three years.

Help employers find you! Check out all the jobs and post your resume.